Le Lézard
Classified in: Health
Subject: SVY

Study: French Grape Seed OPCs Suppress Tumor Formation in Cancer


DALLAS, March 21, 2018 /PRNewswire/ -- While the ability of grape seed extract's oligomeric proanthocyanidins (OPC) to prevent tumors has been previously demonstrated, the underlying mechanisms have not been fully explored. A recent study, published in the journal Scientific Reports, has found several pathways by which a form of French grape seed OPC called VX1 prevents cancer, suppresses tumor formation, and inhibits tumor activity. [Toden S, Ravindranathan P, Gu J, Cardenas J, Yuchang M, Goel A. Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer. Sci Rep. 2018 Feb 20;8(1):3335]

One of the most important findings was the way that OPCs from grape seed interfere with the ability of cancer stem cells to self-renew, and to re-emerge months or years after cancer treatment is completed.

"Cancer stem cells are able to hide, and are able to resist chemotherapy and other treatments," said Ajay Goel, Ph.D., Professor and Director, Center of Gastroenterology, Translational Genomics and Oncology, Baylor Scott & White Research Institute, Baylor University Medical Center, Dallas, TX, the lead author and principal investigator of the study.

"That is why cancer can recur at later dates. The cancer stem cells come out of hiding and start to proliferate. Unfortunately, these new cancer cells are highly resistant to chemotherapy. Finding an effective compound that suppress cancer stem-cell formation in the first place is extremely promising for long-term cancer survival. In this study, we demonstrated that OPCs from French grape seed suppress the creation of cancer stem cells in colorectal cancer, which shows great therapeutic potential. That is in addition to its ability to activate anti-cancer pathways in the body to prevent cancer and to slow tumor growth," stated Dr. Goel.

"This study was unique in that it not only showed the efficacy of OPCs in cancer cell lines, but also validated these findings in reducing colorectal cancer formation in an animal model. More importantly, the ability of OPCs to suppress cancer stem cell formation was confirmed using a new technique in which cells are harvested from a patient's colon cancer tumor and developed into a 3D-tumor organoids in a laboratory setting. This is a unique approach that can be used for studying the effect of an anti-cancer compound in the patient's own specific cancerous tumor. This validation provides a lot more confidence in these data for their validity in a human application," continued Dr. Goel.

It is important to note that the form of French grape seed extract used in the study, VX1, has unique specifications, including standardization for only low molecular weight, high absorption OPCs and containing no tannins. Therefore, results may not apply to other forms of grape seed extract.

For more information on the study, please contact Hilary Hancock at [email protected] or 858-334-3078.

About Dr. Ajay Goel, Ph.D.

Dr. Ajay Goel, Ph.D., is a professor and the director of translational genomics and oncology, as well as the director of the Center for Gastrointestinal Research at the Baylor Scott & White Research Institute, Baylor University Medical Center in Dallas, Texas. One of the top scientists in the world, Dr. Goel investigates botanical interventions and has dedicated over 20 years to cancer research. Dr. Goel is also a leading author or contributor to more than 225 scientific articles published in peer-reviewed international journals and several book chapters, and the primary inventor on more than 15 international patents aimed at developing various biomarkers for the diagnosis, prognosis and prediction of gastrointestinal cancers. Dr. Goel is a member of the American Association for Cancer Research and the American Gastroenterology Association, and works privately with an organization in India to provide food, shelter, education and care for orphaned children.

Media Contact:
Hilary Hancock
Rachel Kay Public Relations
[email protected]
858-334-3078

 

SOURCE Ajay Goel, Ph.D.


These press releases may also interest you

at 17:45
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...

at 17:44
United Breast Cancer Foundation (UBCF) is proud to host a heartfelt event dedicated to honor the memory of Audrey Beverly Christy Mastroianni, a remarkable Rhode Island woman who bravely battled breast cancer. The "Gifts of Comfort and Hope" Mattress...

at 17:31
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...

at 17:31
DelveInsight's Corneal Implant Market...

at 17:26
In observance of National Infertility Awareness Week (April 21-27, 2024), Inception Fertilitytm, a global leader of fertility services, and The Prelude Network®, Inception's clinical network and the largest network of fertility providers in North...

at 17:25
The global ursodeoxycholic acid market  size is estimated to grow by USD 358.41 million from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of  10.65%  during the forecast period. Liver diseases, including cirrhosis and...



News published on and distributed by: